Longeveron (LGVN) Gross Margin (2020 - 2026)
Longeveron's (LGVN) quarterly Gross Margin came in at 66.33% in Q1 2026, down 585.0% year-on-year from 13.68% in Q1 2025, and down 5.79% quarter-over-quarter from 70.41% in Q4 2025.
Longeveron (LGVN) Gross Margin (2020 - 2026) Analysis & Trends
Longeveron's Gross Margin history runs 7 years deep, the most recent figure standing at 66.33% for Q1 2026.
- On a quarterly basis, Gross Margin fell 585.0% year-over-year to 66.33% in Q1 2026; TTM through Mar 2026 was 65.13%, a 1716.0% decrease from a year earlier, with the FY2025 full-year figure at 66.97%, down 1179.0% from the prior year.
- Gross Margin retreated to 66.33% in Q1 2026 per LGVN's latest filing, from 70.41% in the prior quarter.
- Across five years, Gross Margin topped out at 92.0% in Q3 2022 and bottomed at 45.45% in Q4 2022.
- The 5-year median for Gross Margin is 60.04% (2024), against an average of 52.53%.
- Across the five-year window, Gross Margin slumped 7847 bps in 2022 and jumped 9107 bps in 2024, its largest moves.
- Year by year, Gross Margin stood at 45.45% in 2022, then soared by 93 bps to 3.17% in 2023, then jumped by 2869 bps to 87.89% in 2024, then decreased by 20 bps to 70.41% in 2025, then retreated by 6 bps to 66.33% in 2026.
- Per Business Quant, the three latest LGVN Gross Margin figures stand at 66.33% (Q1 2026), 70.41% (Q4 2025), and 91.24% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 66.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.33% |
| Dec 31, 2025 | 70.41% |
| Sep 30, 2025 | 91.24% |
| Jun 30, 2025 | 46.20% |
| Mar 31, 2025 | 72.18% |
| Dec 31, 2024 | 87.89% |
| Sep 30, 2024 | 88.23% |
| Jun 30, 2024 | 73.50% |
| Mar 31, 2024 | 60.04% |
| Dec 31, 2023 | -3.17% |
| Sep 30, 2023 | 36.00% |
| Jun 30, 2023 | 42.86% |
| Mar 31, 2023 | 27.24% |
| Dec 31, 2022 | -45.45% |
| Sep 30, 2022 | 92.00% |
| Jun 30, 2022 | 34.33% |
| Mar 31, 2022 | 53.23% |
| Dec 31, 2021 | 33.01% |
| Sep 30, 2021 | 70.69% |
| Jun 30, 2021 | 42.54% |